{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:32:05Z","timestamp":1782387125241,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejpb.2026.115099","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:30:01Z","timestamp":1778945401000},"page":"115099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS\/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling"],"prefix":"10.1016","volume":"225","author":[{"given":"Rahul","family":"Khemchandani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Pardhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"Bhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Pimpre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Chandra Mouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandkumar","family":"Doijad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh Kumar","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol G","family":"Dikundwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gananadhamu","family":"Samanthula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115099_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137045","article-title":"Design, development and characterization of the Apremilast and Indomethacin coamorphous system","volume":"1299","author":"Pardhi","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115099_b0010","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1080\/07391102.2024.2308048","article-title":"Monophasic coamorphous sulpiride: a leap in physicochemical attributes and dual inhibition of GlyT1 and P-glycoprotein, supported by experimental and computational insights","volume":"43","author":"Pardhi","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejpb.2026.115099_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127225","article-title":"Enhancing solubility, bioavailability and anti-cancer efficacy of aprepitant through a naringin-based co-amorphous system","volume":"425","author":"Pardhi","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2026.115099_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125056","article-title":"Multi-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis","volume":"669","author":"Khemchandani","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.106963","article-title":"Enhanced bioavailability and therapeutic efficacy of Ibrutinib and naringenin-loaded self-nanoemulsifying drug delivery system","volume":"109","author":"Jati","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115099_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2026.114986","article-title":"Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole\u2013succinic acid","volume":"220","author":"Santos Goes","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214542","article-title":"PEGylated liposomes co-encapsulating darolutamide and hesperetin for enhanced prostate cancer therapy: 2D, 3D PC3 models and in-vivo evaluation","volume":"180","author":"Patil","year":"2026","journal-title":"Biomaterials Advances."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115099_b0040","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1021\/acsabm.5c01473","article-title":"Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling","volume":"8","author":"Pardhi","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.ejpb.2026.115099_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126283","article-title":"Integrated experimental, computational and machine learning approaches for the development of Apremilast-Aceclofenac coamorphous systems","volume":"686","author":"Khemchandani","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115099_b0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14656566.2015.1034107","article-title":"Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis","volume":"16","author":"Abdulrahim","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2026.115099_b0055","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2147\/JPR.S326101","article-title":"A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders","volume":"14","author":"Iolascon","year":"2021","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ejpb.2026.115099_b0060","doi-asserted-by":"crossref","unstructured":"E.R. Pardhi R. Patil K.K. Bansal N.K. Mehra Recent Breakthroughs in Nanocrystal Development. Nanocrystal Technologies in Biomedical Sciences: advances in crystal development, characterization and targeted drug delivery 2026: 10.1007\/978-981-95-2968-1_8 207 \u201331.","DOI":"10.1007\/978-981-95-2968-1_8"},{"key":"10.1016\/j.ejpb.2026.115099_b0065","article-title":"Recent advances in Glimepiride Solubility Improvement: a Focus on Formulation Technologies \u2013 a Narrative Review","volume":"21(null):1\u201315","author":"Fiftianingrum","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2026.115099_b0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejpb.2019.06.029","article-title":"Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model","volume":"142","author":"Lombardo","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115099_b0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.molpharmaceut.5c00513","article-title":"Drug\u2013Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance","volume":"23","author":"Bhale","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2026.114988","article-title":"A new drug-drug co-amorphous system of imipramine and celecoxib with improved solubility and synergistic antinociceptive effects","volume":"220","author":"Chen","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114972","article-title":"Sulfasalazine\u2013quercetin co-amorphous systems: Sustained release behaviors and enhanced pharmacokinetics","volume":"220","author":"Deng","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115099_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103863","article-title":"Recent advances in dual-drug co-amorphous systems","volume":"29","author":"Shelke","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115099_b0095","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11095-025-03849-9","article-title":"Advances in Physiologically based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to support Oral Drug Product Development and Harmonization","volume":"42","author":"Cheng","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115099_b0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejpb.2018.11.012","article-title":"Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001","volume":"134","author":"Nothnagel","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2020.09.004","article-title":"Pulmonary drug absorption and systemic exposure in human: predictions using physiologically based biopharmaceutics modeling","volume":"156","author":"Eriksson","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2023.03.014","article-title":"Conjunction of semi-mechanistic in vitro-in vivo modeling and population pharmacokinetics as a tool for virtual bioequivalence analysis - a case study for a BCS class II drug","volume":"186","author":"Danielak","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115099_b0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12249-020-01643-x","article-title":"Understanding the Oral Absorption of Irbesartan using Biorelevant Dissolution Testing and PBPK Modeling","volume":"21","author":"Kaur","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115099_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-024-02990-9","article-title":"Physiologically based Biopharmaceutics Modeling coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: a tough Nut to Crack","volume":"26","author":"Kollipara","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115099_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2021.05.003","article-title":"A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data","volume":"165","author":"Li","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114943","article-title":"Prediction of in vivo behavior of nanoparticles using physiologically based pharmacokinetic model: the modeling approach and issues","volume":"219","author":"Wang","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114874","article-title":"Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets","volume":"216","author":"Zidan","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"53","key":"10.1016\/j.ejpb.2026.115099_b0140","doi-asserted-by":"crossref","first-page":"33314","DOI":"10.1039\/C7RA04038E","article-title":"In vitro\u2013in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus\u2122","volume":"7","author":"Ali","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2026.115099_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114932","article-title":"In vitro two stage one compartment dumping test data and absorption\/formulation PBBM modeling to explain a bioequivalence failure of valsartan formulations","volume":"218","author":"S\u00e1nchez-Dengra","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpb.2020.02.002","article-title":"The biorelevant simulation of gastric emptying and its impact on model drug dissolution and absorption kinetics","volume":"149","author":"Vrbanac","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0155","doi-asserted-by":"crossref","DOI":"10.1039\/D5AY01136A","article-title":"A highly sensitive LC-MS\/MS method for quantification of AB-38b in rat plasma, liver and kidney tissues: application to a pharmacokinetic study","author":"Pan","year":"2026","journal-title":"Anal. Methods"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115099_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103958","article-title":"Understanding the degradation behavior of masitinib by stress testing, UHPLC, HRMS, NMR, APCI-MS, DFT and prediction of toxicity using in silico tools","volume":"114","author":"Dhiman","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115099_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/sscp.202300180","article-title":"Separation and characterization of hydrolytic degradation product of deucravacitinib by validated high-performance liquid chromatography method and liquid chromatography-mass spectrometry","volume":"7","author":"Golla","year":"2024","journal-title":"Sep. Sci. Plus"},{"key":"10.1016\/j.ejpb.2026.115099_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115517","article-title":"Structural characterization and in silico toxicity prediction of degradation impurities of roxadustat","volume":"234","author":"Mahajan","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"30","key":"10.1016\/j.ejpb.2026.115099_b0175","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1080\/17435889.2024.2405455","article-title":"Niosomal gel improves dermal delivery of nimbolide: a promising approach for treatment of psoriasis","volume":"19","author":"Thatikonda","year":"2024","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115099_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.10167","article-title":"Identification and Structural Characterization of Degradation Products of Tivozanib using LC-Q-TOF-MS\/MS and NMR: an In Silico Approach for Degradation and Toxicity Prediction","volume":"40","author":"Shaikh","year":"2026","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejpb.2026.115099_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115077","article-title":"Structural characterization of novel hydrolytic and oxidative degradation products of acalabrutinib by LC-Q-TOF-MS, H\/D exchange and NMR","volume":"221","author":"Kushwah","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115099_b0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpba.2016.02.008","article-title":"LC-ESI-MS\/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus\u2122","volume":"124","author":"Verma","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115099_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.117078","article-title":"LC-MS\/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib","volume":"266","author":"Meertens","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115099_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2026.116880","article-title":"Central composite design optimization of salting-out assisted liquid-liquid extraction coupled with LC-MS\/MS for sustainable duloxetine bioanalysis in human plasma with application in pharmacokinetic studies","volume":"221","author":"Alosaimi","year":"2026","journal-title":"Microchem. J."},{"key":"10.1016\/j.ejpb.2026.115099_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124694","article-title":"Development and validation of a high-throughput LC-MS\/MS bioanalytical method for the simultaneous quantification of cannabidiol and metabolites in human plasma","volume":"1263","author":"De Palma","year":"2025","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2026.115099_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465559","volume":"1740","author":"Elkady","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejpb.2026.115099_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124576","article-title":"A novel ultra-sensitive LC-MS\/MS method for determination of elobixibat in human plasma; Application to a bioequivalence study on healthy volunteers","volume":"1257","author":"Rezk","year":"2025","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2026.115099_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2020.12.008","article-title":"Quantitative MALDI mass spectrometry imaging for exploring cutaneous drug delivery of tofacitinib in human skin","volume":"159","author":"Handler","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2020.02.014","article-title":"Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects","volume":"150","author":"Hens","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0230","unstructured":"USFDA Bioanalytical-Method-Validation-Guidance-for-Industry GUIDANCE DOCUMENT. 2018 doi https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"10.1016\/j.ejpb.2026.115099_b0235","unstructured":"ICH Bioanalytical method validation and study; sample analysis; M10 ICH HARMONISED GUIDELINE. 2022 doi https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf."},{"key":"10.1016\/j.ejpb.2026.115099_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114724","article-title":"Incorporating the biphasic system to GIS-\u03b1 Improves In vivo prediction for low solubility drugs","volume":"211","author":"Naing","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114815","article-title":"Age-dependent oral drug absorption in children: Assessment of a bottom-up modelling approach","volume":"214","author":"Winter","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115099_b0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejps.2014.10.016","article-title":"Parameterization of small intestinal water volume using PBPK modeling","volume":"67","author":"Maharaj","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115099_b0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1208\/s12249-024-02811-z","article-title":"In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil based on a Physiologically-based Pharmacokinetic ACAT Model","volume":"25","author":"Rahim","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115099_b0260","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s11095-016-1951-z","article-title":"Evaluation of the GastroPlus\u2122 Advanced Compartmental and Transit (ACAT) Model in Early Discovery","volume":"33","author":"Gobeau","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115099_b0265","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/9781119987260.ch14","article-title":"Application of PBPK Modeling in Formulation Development","volume":"40","author":"Liu","year":"2024","journal-title":"Exploring Computational Pharmaceutics - AI and Modeling in Pharma"},{"key":"10.1016\/j.ejpb.2026.115099_b0270","article-title":"Formulation strategy of BCS-II Drugs by Coupling Mechanistic In-Vitro and Nonclinical In-Vivo Data with PBPK: Fundamentals of Absorption-Dissolution to Parameterization of Modelling and simulation","volume":"26(5):106","author":"V A S, Nayak UY, Sathyanarayana MB, Chaudhari BB, Bhat K.","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115099_b0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-025-01190-y","article-title":"Exploration of IVIVC Deconvolution Methods in a PBPK Platform: Case example with Tofacitinib","volume":"28","author":"Hens","year":"2026","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115099_b0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2023.06.002","article-title":"The effects of degree and duration of supersaturation on in vivo absorption profiles for highly permeable drugs, dipyridamole and ketoconazole","volume":"189","author":"Higashino","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115099_b0285","first-page":"369","article-title":"Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of positive Food effect for BCS II\/IV Drugs","volume":"64","author":"Rodriguez-Fernandez","year":"2025","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115099_b0290","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1208\/s12249-013-0018-2","article-title":"Utility of Physiologically based Modeling and Preclinical In Vitro\/In Vivo Data to Mitigate positive Food effect in a BCS Class 2 compound","volume":"14","author":"Xia","year":"2013","journal-title":"AAPS PharmSciTech"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:25:08Z","timestamp":1781234708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"alternative-id":["S0939641126001207"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115099","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS\/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115099"}}